ANDROGRAPHIS PANICULATA

Non-communicable diseases like high blood pressure, diabetes, and glaucoma cause serious health issues and hardships in sub-Saharan Africa, often made worse by a lack of access to regular medical services. This research examines how the leaf extracts from Sorghum bicolor and Andrographis paniculata affect blood pressure, blood sugar, and eye pressure in healthy adults, both separately and together. One hundred and seventy-four (174) participants (mean age 34.3 ± 7.1 years) received single administrations of hot aqueous extracts of S. bicolor, A. paniculata, or a 1:1 mixed extract. Systolic and diastolic blood pressure (mmHg), fasting blood glucose (mg/dL) and IOP (mmHg, right eye [RE] and left eye [LE]) were measured at baseline and four hours post- administration. The results revealed statistically significant reductions (p < 0.05) across all parameters in all treatment groups. For Sorghum bicolor, systolic pressure decreased from 126.15 ± 15.9 to 120.80 ± 15.0 mmHg, diastolic pressure from 85.60 ± 11.1 to 80.03 ± 10.4 mmHg, blood glucose from 82.86 ± 14.61 to 70.39 ± 11.99 mg/dL, and IOP from 16.88 ± 2.5 to 15.83 ± 1.6 mmHg (right eye) and from 17.14 ± 1.93 to 16.12 ± 1.8 mmHg (left eye). Similar reductions were observed with Andrographis paniculata, where systolic pressure fell from 129.44 ± 14.7 to 121.20 ± 16.9 mmHg, diastolic pressure from 84.60 ± 13.3 to 77.13 ± 11.4 mmHg, and blood glucose from 83.61 ± 13.2 to 75.26 ± 11.43 mg/dL, while IOP decreased to 14.49 ± 2.0 mmHg (right) and 15.98 ± 2.0 mmHg (left). The combined extract produced the greatest effect, with systolic pressure reducing from 134.63 ± 15.7 to 128.68 ± 15.9 mmHg, diastolic pressure from 87.10 ± 22.1 to 77.90 ± 12.2 mmHg, blood glucose from 80.42 ± 12.04 to 74.40 ± 10.20 mg/dL, and IOP from 15.94 ± 1.8 to 14.94 ± 2.0 mmHg (right) and 15.67 ± 1.5 to 15.13 ± 2.7 mmHg (left). These results demonstrate that both Sorghum bicolor and Andrographis paniculata extracts—singularly and in combination—can significantly lower blood pressure, blood glucose, and intraocular pressure within a short period following administration. The enhanced effects observed with the combined extract suggest possible synergistic interactions between their phytochemical constituents.

The outbreak of COVID-19, caused by SARS-CoV-2, has created an urgent need for new and more effective antiviral agents, particularly those derived from natural sources. Andrographis paniculata (Burm.f.) Nees (Acanthaceae), commonly known as the King of bitters, is a medicinal plant valued for its antiviral and immunomodulatory properties. This study aimed to investigate the therapeutic potential of phytochemicals from Andrographis paniculata as inhibitors of the SARS-CoV-2 virus (PDB ID:7BV2) using molecular docking and ADMET predictions. The 3D structure of the SARS-CoV-2 protein was obtained from the RCSB PDB. Amino acids at the binding site of the protein were identified using PLIP. The protein was prepared for docking in BIOVIA Discovery Studio. Phytochemicals isolated from the plant and identified using GC-MS were downloaded from PubChem as SDF files and imported into PyRx for molecular docking. Post-docking interaction was analysed in BIOVIA Discovery Studio. The ADMET predictions of the phytochemicals were done using the Swiss ADME web server and ProTox-3.0. Molecular docking results from 90 isolated compounds and 23 compounds from GC-MS analysis revealed 27 isolated compounds with a binding affinity range of -6.9 to -8.5 kcal/mol against the target protein, as compared to the standard drug (Remdesivir Triphosphate) and co-crystallized ligand (F86) with binding affinities of -7.7 and -6.8 kcal/mol, respectively. These 27 compounds were selected for post-docking analysis and ADMET profiling. Andrographis paniculata (Burm.f.) Nees (Acanthaceae) possesses phytoconstituents with potential inhibitory activity against the SARS-CoV-2 protein. Methyl 3,4-dicaffeoylquinate, identified as the top compound, along with 5-Hydroxy-7,2',6'-trimethoxyflavone, 5,7,2',6'- Tetrahydroxyflavone, and Apigenin showed good absorption, distribution, metabolism, elimination (ADME), and a comparatively safe toxicity profile. Therefore, further experimental validation is required to confirm their therapeutic potential as antiviral agents against SARS-CoV-2